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Objective: The aim of this article is to compare the efﬁcacy and safety of doripenem for
bacterial infections.
Methods: We  included six randomized clinical trials identiﬁed from PubMed and Embase
up  to July 31, 2014. The included trials compared efﬁcacy and safety of doripenem for
complicated intra-abdominal infections, complicated urinary tract infection, nosocomial
pneumonia, and acute biliary tract infection. The meta-analysis was carried on by the
statistical software of Review Manager, version 5.2.
Results: Compared with empirical antimicrobial agents on overall treatment efﬁcacy,
doripenem was associated with similar clinical and microbiological treatment success rates
(for the clinical evaluable population, odds ratio [OR] = 1.26, 95% conﬁdence interval [CI]
0.93–1.69, p = 0.13; for clinical modiﬁed intent-to-treatment population, OR = 0.88, 95% CI
0.55–1.41, p = 0.60; for microbiology evaluable population, OR = 1.16, 95% CI 0.90–1.50, p = 0.26;
for  microbiological modiﬁed intent-to-treatment (m-mITT), OR = 0.98, 95% CI 0.81–1.20,
p  = 0.87). We  compared incidence of adverse events and all-cause mortality to analyze treat-
ment  safety. The outcomes suggested that doripenem was similar to comparators in terms of
incidence of adverse events and all-cause mortality on modiﬁed intent-to-treatment pop-
ulation (for incidence of AEs, OR = 1.10, 95% CI 0.90–1.35, p = 0.33; for all-cause mortality,
OR = 1.08, 95% CI 0.77–1.51, p = 0.67). In nosocomial pneumonia and ventilator-associated
pneumonia treatment, doripenem was not inferior to other antibacterial agents in terms of
efﬁcacy and safety.
Conclusion: From this meta-analysis, we can conclude that doripenem is as valuable and
well-tolerated than empirical antimicrobial agents for complicated intra-abdominal infec-tions, complicated urinary tract infection, acute biliary tract infection and nosocomial
pneumonia treatment.
© 2015 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author at: Xinmin Street 71#, Changchun City, PR Chin
E-mail address: 350740439@qq.com (X.-Y. Qu).
http://dx.doi.org/10.1016/j.bjid.2014.10.010
1413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.a.
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ntibacterial agents of the carbapenem class are assuming
 more  important role in the treatment of severe bacte-
ial infections. Doripenem, a new parenteral carbapenem,
as been recognized as a valuable addition to the cur-
ently available carbapenems in the treatment of serious
nfections. Doripenem has a broad spectrum of in vitro
ctivity against Gram-positive and Gram-negative bacteria,
ncluding multi-drug resistant bacteria that have been a
igniﬁcant cause of morbidity and mortality.1 In the USA,
oripenem is the most recent US Food and Drug Admin-
stration (FDA)-approved carbapenem for the treatment of
atients with complicated intra-abdominal infection (cIAI),
omplicated urinary tract infection (cUTI) and pyelonephri-
is. Doripenem is approved in Europe and in other countries
or the treatment of patients with cIAI, cUTI and nosocomial
neumonia (NP), including ventilator-associated pneumo-
ia (VAP).2 However, a statement about doripenem was
ssued from the FDA, in May 2012, stating that the clin-
cal trial for VAP treatment with doripenem had been
erminated early due to signiﬁcant safety concerns. The
rial initiated by Kollef et al. was aimed at evaluating the
ffects of doripenem on treatment of patients with VAP,
emonstrated excess mortality and a numerically poorer
linical cure rate among doripenem-treated subjects com-
ared to those treated with imipenem–cilastatin.3,4 In March
014, the FDA issued further safety information stating
he approved doripenem label changes for highlighting
he increased risk of death for ventilator patients with
neumonia.5 By now, several randomized controlled trials
RCTs) have assessed doripenem efﬁcacy and safety com-
ared to some empirical antimicrobial agents, including three
rials evaluating NP and VAP treatment. So far, however,
here is no systematic review and meta-analysis compar-
ng the efﬁcacy and safety of doripenem and comparators
or treating bacterial infections. Although a meta-analysis
as published by Jenkins in 2009, it was limited to patients
ith Pseudomonas infections enrolled in four clinical trials.6
herefore, we  performed a comprehensive and updated
eta-analysis to provide better evidence of the efﬁcacy and
afety doripenem on treating bacterial infections, especially
ocused on treatment efﬁcacy and safety for NP and VAP
atients.
ethods
ligibility  criteria
o be eligible a study would have to be designed as a RCT that
irectly compared efﬁcacy or safety of doripenem with any
ther active antimicrobial agents for treating bacterial infec-
ions.
Retrospective studies were excluded, as well as those
ocused on in vitro susceptibility testing, experimental
nimal studies or pharmacokinetic–pharmacodynamic eval-
ations.5;1 9(2):156–162 157
Outcome  measures
The primary outcome measure was clinical treatment efﬁcacy
on clinical evaluable (CE) population and clinical modi-
ﬁed intent-to-treatment (c-mITT) population. The secondary
outcomes were microbiological treatment success rates on
microbiology evaluable (ME) population and microbiological
modiﬁed intent-to-treatment (m-mITT) population. At last,
AEs and all-cause mortality on modiﬁed intent-to-treatment
(m-ITT) population were assessed.
The details and deﬁnitions for study populations were
demonstrated as followed: (i) mITT: patients who received
at least one dose of study drugs; (ii) c-mITT: patients who
met  minimum disease criteria on mITT population; (iii) CE:
patients who did not receive confounding doses of prior
or concomitant study drugs, received sufﬁcient therapeutic
doses, and had a test-of-cure (TOC) efﬁcacy assessment per
protocol on c-mITT population. (iv) m-mITT: patients who had
at least one baseline isolate on c-mITT population; and (vi) ME:
patients who had at least one baseline isolate susceptible to
each regimen and had a microbiologic response assigned on
CE population.
Information  sources  and  literature  search
Publications at PubMed and Embase data sets up to July 31,
2014 were reviewed with the search strategies “doripenem” or
“Doribax” and “efﬁcacy”, “safety”, “infection” or “randomized
controlled trials”.
Study  selection  and  data  extraction
Two reviewers (Qu and Hu) searched and examined the pub-
lications independently. The included studies were examined
separately according to the eligibility criteria described above.
Evaluation of the methodological quality of the RCTs was per-
formed by two reviewers independently according to the Jadad
scoring system.7 The high quality trials were awarded three or
more points with a maximum of ﬁve points. When disagree-
ment occurred, a third author (Zhou) resolved the problem in
time. The following data were extracted from every included
study: year of publication, type of infection, patient popula-
tion, drug information, clinical and microbiological outcomes
of treatment, incidence of AEs, and all-cause mortality.
Statistical  analysis
The software Review Manager, version 5.2 was used to con-
duct the statistical analyses. Heterogeneity was evaluated
with Q statistic generated from the 2 test and inconsistency
with I2 measure.8 Heterogeneity was considered signiﬁcant
when p-value was less than 0.10 or I2 more  than 50%. A
Mantel–Haenszel ﬁxed-effect model (FEM) with pooled odds
ratio (OR) and 95% conﬁdence interval (CI) was used for out-
come analyses when heterogeneity was not signiﬁcant. When
heterogeneity was obvious DerSimonian and Laird random-
effects model (REM) was used for outcome analysis.
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Potentially relevant articles:
PubMed (n=102); Embase (n=45)
Trails retrieved for further evaluation (n=12)
Studies were excluded on screening
abstract/titles for inclusion criteria and
duplicate retrieval (n=135)
Studies were excluded due to lack of randomized
controlled trials, researched activity in vitro and
repeated arctiles (n=6)
Studies included on final analysis (n=6)
electFig. 1 – Flow diagram for s
Results
Study  selection  outcomes
The ﬂow diagram in Fig. 1 shows the details of the study
selection process. The studies were selected with the search
programs and inclusion criteria previously determined. In
total, six trials,3,9–13 which fulﬁlled all inclusion criteria, were
included in this meta-analysis.
Study  characteristics
Table 1 shows the following characteristics of the included
RCTs: study design, type of infection, number of patients
(mITT), mean age, drug information, and Jadad score. The
meta-analysis was composed of six RCTs for cIAI, cUTI, acute
biliary tract infection (aBTI) and NP, including VAP. All included
studies were RCTs conducted between 2008 and 2014. Five
of six trials were multinational studies. The total sample
of the included trials was 2542 subjects and all trials were
conducted exclusively in adults. The meta-analysis included
comparisons of doripenem with imipenem–cilastatin,
meropenem, levoﬂoxacin, and piperacillin/tazobactam. Sub-
jects in doripenem group received doripenem at doses of 1 g
or 0.5 g every 8 h. The mean Jadad score of the six publication
RCTs was 3.5 (rang 2–5). The higher the Jadad score the better
the quality of the meta-analysis.
Clinical  and  microbiological  treatment  success
Clinical treatment success rate on the CE sample was pro-
vided in four trials totaling 1427 subjects. The doripenem
group was associated with higher rate of clinical treatment
success, but the difference was not signiﬁcant (OR = 1.26, 95%
CI 0.93–1.69, p = 0.13, Fig. 2A). Data on c-mITT population were
also provided in four trials with 1272 subjects. In contrary, the
clinical treatment success rate of doripenem group was lower
than comparator group (OR = 0.88, 95% CI 0.55–1.41, p = 0.60,
Fig. 2B), but again the difference was not signiﬁcant. Theion of the RCTs reviewed.
overall meta-analysis of clinical treatment success suggested
that doripenem was as effective as comparators for treating
bacterial infections.
Four of the six trials reported microbiological treatment
success on ME sample, and all trials provided data on c-
mITT sample. There were 1257 subjects and 1980 subjects on
ME and c-mITT samples, respectively. In both comparisons,
doripenem was as effective as comparators (for ME  popula-
tion, OR = 1.16, 95% CI 0.90–1.50, p = 0.26, Fig. 2C; for m-mITT
population, OR = 0.98, 95% CI 0.81–1.20, p = 0.87, Fig. 2D).
Outcomes  of  treatment  safety
Treatment safety was assessed by meta-analysis in terms
of AEs incidence and all-cause mortality risk. Five trials
provided relevant AEs outcomes. According to the data of
meta-analysis, doripenem was numerically higher than com-
parators on incidence of AEs, but the difference was not
signiﬁcant (3313 subjects, OR = 1.10, 95% CI 0.90–1.35, p = 0.33,
Fig. 3A). All-cause mortality during the study period was avail-
able in four of the included trials. Although numerically higher
mortality in the doripenem groups could be seen, there was
no signiﬁcant difference between doripenem and compara-
tor group (1592 subjects, OR = 1.08, 95% CI 0.77–1.51, p = 0.67,
Fig. 3B).
Evaluation  of  efﬁcacy  and  safety  for  NP  and  VAP
treatment
There were three trials [3,10,13] comparing doripenem
with comparators for pneumonia treatment, two trials
for VAP and one for NP. The comparator drugs were
piperacillin/tazobactam and imipenem–cilastatin. The meta-
analysis of outcomes shown in Table 2 demonstrates that the
doripenem group was associated with higher rates of treat-
ment success on CE and ME sample. In contrast, doripenem
group was associated with lower rates on c-mITT and m-mITT
samples. However, the differences of clinical and microbiolog-
ical treatment successes were not signiﬁcant.
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Table 1 – The main characteristic of included trials.
Study ID Study design Type of infection Number of patients Age(years),mean(SD) Drug information Study quality
Expe Comp Expe Comp Expe Expe
Chastre2008 Multicentre,
randomized, open
label, phase 3
VAP 262  263 50.7 (19.6) 50.3 (19.0) Doripenem 0.5 g q8 h
via a 4-h IV
Imipenem 0.5 g q6 h via
a 30 min IV or 1 g q8 h
via a 60-min IV
2
Kollef2012 Multicentre,
randomized, double
blind, phase 3
VAP 115  112 57.5(16.5) 54.6 (18.5) Doripenem 1 g q8 h
via a 4-h IV
Imipenem/cilastatin 1 g
q8 h via a 1-h IV
5
Lucasti2008 Multicentre,
randomized, double
blind, phase 3
cIAI  235 236 46.9 (18.1) 46.4 (17.5) Doripenem 0.5 g q8 h
IV over 1 h
Meropenem 1 g q8 h via
20-mL IV bolus over
3–5 min
5
Naber2009 Multicentre,
randomized, double
blind, phase 3
cUTI 377 376 51.2 (21.1) 51.1 (21.0) Doripenem 0.5 g,
q8 h, i.v.gtt
Levoﬂoxacin 0.25 g, qd,
i.v.gtt
5
Neto2008 Multicentre,
randomized, open
label, phase 3
NP  223 221 57.5 (19.2) 59.3(18.9) Doripenem 0.5 g,
q8 h, i.v.gtt over 1 h
Piperacillin/tazobactam
4.5 g, q6 h via a 30 min IV
2
Tazuma2014 Randomized, open
label
aBTI 58 64 74 (11.5) 73 (12.8) Doripenem 0.5 g,
q8 h, i.v.gtt over
30 min or 1 h
Imipenem/cilastatin
0.5 g, q8 h, i.v.gtt over
30 min or 1 h
2
Expe, experimental group; Comp, comparator group; VAP, ventilator-associated pneumonia; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; NP, nosocomial
pneumonia; aBTI, acute biliary tract infection; IV, intravenous injection; i.v.gtt, intravenous drip; q8 h, every 8 h.
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Study or Subgroup
Doripenem Comparators
Weight
Odds ratio Odds ratio
Events    total Events Total M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Study or Subgroup
Doripenem Comparators
Weight
 Odds ratio Odds ratio
Events     total Events Total M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Study or Subgroup
Doripenem Comparators
Weight
 Odds ratio Odds ratio
Events      total Events Total M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Study or Subgroup
Doripenem Comparators
Weight
 Odds ratio Odds ratio
Events    total Events Total M-H, Random, 95% CI M-H, Random, 95% CI
Chastre2008
Lucasti2008
Naber2009
Neto2008
Chastre2008
Kollef2012
Neto2008
Tazuma2014
147
47
148
54
249
115
213
58
146
67
134
60
252
112
209
64
33.2%
26.9%
31.4%
8.5%
86
163
272
109
126
188
286
134
79
161
240
95
122
186
266
119
32.7%
27.6%
15.6%
24.1%
1.17 [0.69, 1.98]
1.01 [0.56, 1.84]
2.10 [1.07, 4.12]
1.10 [0.59, 2.06]
1.26 [0.93, 1.69]
1.05 [0.73, 1.49]
0.46 [0.27, 0.79]
1.27 [0.85 ,1.91]
0.90 [0.21, 3.78]
0.88 [0.55, 1.41]
1.22 [0.70, 2.12]
1.37 [0.88, 2.12]
0.92 [0.59 ,1.43]
1.27 [0.59, 2.74]
0.16 [0.90, 1.50]
0.97 [0.65, 1.43]
0.64 [0.35, 1.17]
1.27 [0.79 ,2.03]
1.06 [0.73, 1.55]
1.01 [0.62, 1.66]
0.62 [0.24, 1.62]
0.98 [0.81, 1.20]
Total (95% CI)
Total events
Heterogeneity: Chi2=3.01, df=3 (P=3.39): I2=0%
Test for overall effect: Z=1.51 (P=0.13)
Total (95% CI)
Total events
Heterogeneity: Tau2=0.14; Chi2=9.31, df =3 (P=0.03); I2 =68%
Test for overall effect: Z=0.52 (P=0.60)
Chastre2008
Lucasti2008
Naber2009
Neto2008
Total (95% CI)
Total events
Heterogeneity: Chi2=1.71, df = 3 (P=0.64); I2=0%
Test for overall effect: Z=1.13 (P=0.26)
Chastre2008
Killerf2012
Naber2009
Neto2008
Tazuma2014
Total (95% CI)
Total events
Heterogeneity: Chi2=4.12, df =5 (P=0.53); I2=0%
Test for overall effect: Z=0.17 (P=0.87)
630
396
635
407
637 100.0%
575
743 693 100.0%
0.05 0.2 1 5 20
Doripenem Comparators
0.05 0.2 1 5 20
Doripenem Comparators
0.05 0.2 1 5 20
Doripenem Comparators
0.05 0.2 1 5 20
Doripenem Comparators
80
89
230
69
119
36
153
259
94
29
206
79
195
327
139
42
119
50
141
251
97
36
203
88
190
321
144
46
25.1%
12.8%
15.3%
26.2%
15.3%
5.3%
116
163
280
84
71
73
221
65
110
156
265
83
20.8%
31.2%
37.3%
10.7%
468
643
430
614 100.0%
988
690 694 992 100.0%
A
B
C
D
Fig. 2 – The meta-analysis of doripenem and 
Table 2 – The outcomes of meta-analysis for pneumonia
treatment.
Population No. patients OR 95% CI p value
CE 353 1.1 0.59–2.06 0.76
c-mITT 1150 0.88 0.52–1.49 0.63
ME 393 1.24 0.79–1.94 0.35
m-ITT 859 0.9 0.68–1.18 0.45
meta-analysis which only assessed patients infected by Pseu-AEs 969 0.94 0.67–1.31 0.72
All-cause mortality 1121 1.12 0.79–1.59 0.53
Regarding safety, although numerically higher mortality in
the doripenem group was observed, there was no signiﬁcant
difference between the doripenem and comparator groups.
Drug-related AEs in the doripenem group were numericallycomparator groups on treatment efﬁcacy.
lower than in the comparator groups without signiﬁcance. The
outcomes of meta-analysis for pneumonia treatment showed
that doripenem was as effective as comparator drugs, with
non-signiﬁcant higher occurrence of AEs and all-cause mor-
tality.
Discussion
As far as we know, in contrast to the earlier doripenemdomonas, this is the ﬁrst meta-analysis assessing the efﬁcacy
and safety of doripenem treatment for overall bacterial
infections.6 Furthermore, we focused on the efﬁcacy and
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Study or Subgroup
Doripenem Comparators
Weight
Odds ratio Odds ratio
Events      total Events Total M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Study or Subgroup
Doripenem Comparators
Weight
Odds ratio Odds ratio
Events      total Events Total M-H, Fixed, 95% CI M-H, Fixed, 95% CI
0.98 [0.62, 1.54]
1.31 [0.88, 1.95]
1.14 [0.83 ,1.58]
0.90 [0.55, 1.48]
1.09 [0.15, 7.96]
1.14 [0.65, 2.01]
1.58 [0.71, 3.51]
0.71 [0.22 ,2.27]
0.94 [0.54, 1.61]
0.10 [0.90, 1.35]
Chastre2008
Lucasti2008
Naber2009
Neto2008
Tazuma2014
Chastre2008
Kollef2008
Lucasti2008
Neto2008
Total (95% CI)
Total events
Heterogeneity: Chi2=1.71, df=4 (P=0.79); I2=0%
Test for overall effect: Z=0.98 (P=0.33)
Total (95% CI)
Total events
Heterogeneity: Chi2=1.68, df =3 (P=0.64); I2=0%
Test for overall effect: Z=0.43 (P=0.67)
0.05 0.2 1 5 20
Doripenem Comparators
0.05 0.2 1 5 20
Doripenem Comparators
45
76
106
36
2
262
235
376
223
60
46
63
95
39
2
263
236
372
221
65
20.7%
23.1%
37.3%
17.9%
1.0%
265
1156
245
1157 100.0%
28
17
5
30
80
262
79
235
217
793
25
13
7
31
76
263
88
236
212
799
33.9%
14.7%
10.4%
41.1%
100.0% 1.08 [0.77, 1.51]
A
B
Fig. 3 – The meta-analysis of doripenem and comparator groups on treatment safety.
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iafety of doripenem on NP treatment to conﬁrm the FDA state-
ent. The results of this current meta-analysis demonstrate
hat doripenem is as effective as comparators for bacte-
ial infections, including cIAI, cUTI, aBTI and NP. In terms
f safety, although the incidence of AEs and all-cause mor-
ality with doripenem was slight higher than comparators,
he difference was not signiﬁcant. Regarding NP and VAP,
lthough doripenem has not yet been approved by the FDA,
he outcomes of this meta-analysis show that doripenem is
on-inferior to other antibacterial agents in terms of efﬁ-
acy and safety. In addition, a recent study has demonstrated
 signiﬁcantly shorter length of hospital stay and time on
echanical ventilation of patients with VAP treated with
oripenem compared to imipenem. This study suggests that
oripenem use may be beneﬁcial both economically and clin-
cally to patients.14
The current meta-analysis suggests that there is no sig-
iﬁcant difference between doripenem and comparator drugs
n treatment efﬁcacy and safety, but doripenem remains
 valuable alternative as it has several advantages. First,
 total daily dose of 1.5 g of doripenem is equivalent to
 g of meropenem or 2–3 g of imipenem in terms of clin-
cal and microbiological cure rates. Doripenem does not
equire the addition of cilastatin, and has a lower seizure
otential compared to imipenem. Furthermore, the plasma
aximum concentration of doripenem is higher than that
chieved by imipenem and similar to that of meropenem.15
econd, in vitro studies have shown that doripenem has
reat activity against Enterobacteriaceae and Pseudomonas and
as lower potential to select for decreased drug suscepti-
ility compared with imipenem–cilastatin. Doripenem and
eropenem were the most active compounds against these
solates, both better than imipenem.16 Our ﬁndings supportthe excellent sensitivity to Gram-negative bacteria, includ-
ing Pseudomonas aeruginosa,  Enterobacter cloacae,  Escherichia coli,
Klebsiella pneumoniae. Doripenem therapy is associated with
favorable microbiological treatment success in great majority
of subjects with baseline isolates. Third, concerning treatment
safety, in general, doripenem is well tolerated. The most com-
mon  adverse reactions reported in RCTs are nausea, diarrhea,
headache, rash, and phlebitis. Previous carbapenems have
been considered to induce seizures primarily via inhibition
of -aminobutyric acid (GABA) receptor binding. By contrast,
doripenem has low afﬁnity to the GABA receptor, resulting in
low potential for seizure induction.17
The ﬁnding of our meta-analysis has several limitations:
ﬁrst, we  had no access to unpublished data. Although we
have included conference papers and clinical trial informa-
tion, the meta-analysis still lacks unpublished data. Second,
the small number of subjects becomes a limitation of this
meta-analysis. Third, there was heterogeneity in RCTs such as
patients, comparator drugs, and subjective diversity of clini-
cians.
In conclusion, doripenem is a valuable and well-tolerated
drug that is as effective as empirical antimicrobial agents for
treating cIAI, cUTI, aBTI, and NP. It can play an important role
for patients with serious nosocomial bacterial infections in the
setting of multidrug resistant pathogens, such as Enterobac-
teriaceae and Pseudomonas. However, to obtain more  deﬁnite
conclusions, further investigation on doripenem treatment is
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